AlphAIAlphAI — Financial news for AI agents
tipranks.comSEP 141 min read$CEVA

Ceva upgraded to Buy at StoneX following recent selloff

StoneX upgraded Ceva to Buy from Hold, setting a $42 price target. The firm cited a 30% share price decline since mid-July and potential upside for FY27 and FY28. The analyst also noted possible revenue acceleration as a catalyst.

Original reporting
tipranks.com
Published Sep 14, 2026, 11:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 3:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Ceva upgraded to Buy at StoneX following recent selloff — source image
Source · tipranks.com
Decision brief

The 30-second read

$CEVABullishMed
01

Why it matters

The upgrade provides a fresh catalyst that could drive the stock toward the $42 target, offering a buying opportunity for traders.

02

Market read

The upgrade is a primary piece of company news that may influence Ceva's price action and sector sentiment.

03

What to watch

Potential regulatory risks and competition are not addressed in the upgrade.

Relevance 7/10Novelty 7/10Timing: today

Background

Ceva, a US-listed biotech, received an upgrade from StoneX after a 30% selloff since mid-July.

Company-level read

Ticker impact

$CEVABullishMedium confidence
Context

StoneX upgraded Ceva to Buy from Hold with a $42 price target, citing recent selloff and catalysts.

Expected impact

Share price may rise toward the $42 target.

Evidence & confidence

Upgrade is based on recent selloff, revenue acceleration expectations and FY27/FY28 upside scenario.

Market effects

Sector

Biotech sector may see modest uplift as analyst upgrades signal confidence in pipeline.

Regional

US biotech stocks could benefit from the positive sentiment.

Global

Limited to investors tracking US-listed biotech companies.

Counterpoint

What could challenge this read

The upgrade may be premature if upcoming trial data disappoints.

Key entities

  • Company
    Ceva

    US biotech firm (ticker CEVA).

  • Research Firm
    StoneX

    Analyst firm that issued the upgrade.

Read at source← All news

Related articles

OCT 6
$CRWDMed

CRWD Maintained by StoneX -- Price Target Raised to $325

StoneX analyst Yi Fu Lee maintained a 'Buy' rating on CrowdStrike (CRWD) and raised the price target from $250 to $325. The stock is currently priced at $272.67, which is 97.7% overvalued according to GF Value™. CrowdStrike's GF Score™ is 71/100, indicating strong growth and momentum but poor valuation. Insider activity shows significant selling, with $451 million in sales over the past three months.

gurufocus.com2 min
OCT 6
$TXRHMed

Texas Roadhouse upgraded to Buy from Hold at StoneX

StoneX upgraded Texas Roadhouse to Buy from Hold, setting a $200 price target. The analyst cites the company's leadership in casual dining and compelling risk/reward after a share pullback. Texas Roadhouse is seen as a high-quality operator that can widen its competitive advantage during economic stress.

tipranks.com1 min
OCT 2
$CEVAHighAI 9/10

CMA CGM says FedEx deal nearly triples CEVA's North American contract logistics footprint as forwarding and automotive weigh on its margin

CMA CGM's acquisition of FedEx Supply Chain for $1.4B nearly triples CEVA's North American contract logistics footprint, adding 10,000 employees and 34M sq ft of warehouse space. The deal was completed on 1 October, but forwarding and automotive sectors have reduced CEVA's logistics margin year-over-year.

container-mag.com2 min
OCT 2
$ROCMed

Rank One Computing stock price target maintained at $9 by StoneX

StoneX reiterated a Buy rating and $9 price target for Rank One Computing (NASDAQ:ROC), citing recent contract wins and improved pipeline velocity. The stock has fallen 44.6% over six months, trading at $4.05. The company reported a 2% revenue increase in Q2 2026, with a gross profit margin of nearly 80%. Management extended lock-up agreements until February 2027.

investing.com2 min
SEP 17
$SNEXMed

StoneX (SNEX) Turns Mortgage Bond Complexity Into New Revenue

StoneX Group (SNEX) launched a synthetic credit structure with DeltaTerra for mortgage bonds, enabling institutional investors to gain exposure via credit default swaps. The company reported strong fiscal Q3 results, with revenue up 47% and net income more than doubling. Growth was driven by commercial and institutional segments, while retail segment revenue declined. Interest expenses and variable costs increased, and a new structured product aims to capitalize on a market event. Hedge funds ha

insidermonkey.com2 min